NCT03644342View on ClinicalTrials.gov

Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

July 15, 2019

Primary Completion Date

April 18, 2022

Study Completion Date

September 27, 2023

Conditions
Metastatic Carcinoma of the Cervix
Interventions
DRUG

Nirapaib

(see treatment regimen and method of treatment assignment)

Trial Locations (3)

77030

Baylor College of Medicine, Houston

Baylor St. Luke's Medical Center McNair, Houston

77054

Harris Health System - Smith Clinic, Houston

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Michelle S Ludwig

OTHER

NCT03644342 - Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix | Biotech Hunter | Biotech Hunter